These trials completed more than 12 months ago and should have reported results. Some have, some have not.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
|Status||Trial ID||Title||Completion date||Category|
|Completed, but no date||2006-000644-13||Multicenter, randomized, controlled study to compare palonosetron plus dexamethasone before chemotherapy administration versus the same regimen with dexamethasone continuing on Days 2 and 3 in prevent...||bad-data|
|Completed, but no date||2006-003137-32||A randomized, open label, multicenter phase II study of first line therapy with Sorafenib in association with Interleukin 2 versus Sorafenib alone in patients with unresectable and/or metastatic renal...||bad-data|
|Completed, but no date||2008-001355-21||First Line UFT, OXALIPLATIN and ERBITUX combination (TEGAFOX-E) in Elderly (≥ 70 years) metastatic colorectal patients: a Phase II ITMO study.||bad-data|
|Ongoing||2008-007152-94||Efficacy and Safety of RAD001 (Everolimus) in Patients Affected by Biliary Tract Cancer Progressing After Prior Chemotherapy: a Phase II I.T.M.O. Study||not-yet-due|
|Completed, but no date||2008-007153-13||An open label, single arm, phase II study of combination RAD001 and octreotide LAR in patients with advanced neuroendocrine tumors as first line treatment||bad-data|
|Not reported||2008-008749-39||Capecitabine in combination with Oxaliplatin, Irinotecan and Bevacizumab (COI-B regimen) as First-Line therapy for metastatic colorectal cancer: a Phase II I.T.M.O. study.||2014-03-06||due-trials|
|Completed, but no date||2012-004539-22||An open label, single arm, phase II study to evaluate the activity and toxicity of Panitumumab in pre-treated patients with advanced well differentiated neuroendocrine tumor (G1 and G2)||bad-data|